Obesity remains a critical global health threat, affecting over one billion people worldwide and exacerbating risks for type 2 diabetes, cardiovascular diseases, and fatty liver disease. The pharmaceutical landscape is witnessing rapid transformation through novel oral GLP-1 agents, long-acting injectables, and multi-target therapies that are redefining treatment possibilities.
At the preclinical stage, BioDuro's Diet-Induced Obesity (DIO) rodent models, enhanced with high - resolution phenotyping tools, create a crucial translational bridge to accelerate weight loss drug development.
Key Topics
- Review emerging obesity targets and clinical development progress.
- Compare and select optimal rodent models for obesity research.
- Design effective efficacy studies for weight loss compounds.
- Enhance translation between preclinical and clinical study outcomes.
Whether advancing weight loss programs or exploring novel targets, this webinar delivers practical insights to support your drug development initiatives.
